- Home
- ACRS vs RMBI Comparison
ACRS vs RMBI Comparison
Compare ACRS & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- RMBI
- Stock Information
- Founded
- ACRS 2012
- RMBI 1887
- Country
- ACRS United States
- RMBI United States
- Employees
- ACRS N/A
- RMBI N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- RMBI Major Banks
- Sector
- ACRS Health Care
- RMBI Finance
- Exchange
- ACRS Nasdaq
- RMBI Nasdaq
- Market Cap
- ACRS 165.7M
- RMBI 140.3M
- IPO Year
- ACRS 2015
- RMBI 2019
- Fundamental
- Price
- ACRS $1.95
- RMBI $14.50
- Analyst Decision
- ACRS Strong Buy
- RMBI
- Analyst Count
- ACRS 9
- RMBI 0
- Target Price
- ACRS $9.25
- RMBI N/A
- AVG Volume (30 Days)
- ACRS 891.2K
- RMBI 17.6K
- Earning Date
- ACRS 11-05-2025
- RMBI 10-23-2025
- Dividend Yield
- ACRS N/A
- RMBI 4.14%
- EPS Growth
- ACRS N/A
- RMBI 17.64
- EPS
- ACRS N/A
- RMBI 0.95
- Revenue
- ACRS $16,789,000.00
- RMBI $43,502,862.00
- Revenue This Year
- ACRS N/A
- RMBI N/A
- Revenue Next Year
- ACRS N/A
- RMBI N/A
- P/E Ratio
- ACRS N/A
- RMBI $15.26
- Revenue Growth
- ACRS N/A
- RMBI 4.48
- 52 Week Low
- ACRS $1.05
- RMBI $11.37
- 52 Week High
- ACRS $5.17
- RMBI $15.15
- Technical
- Relative Strength Index (RSI)
- ACRS 56.76
- RMBI 51.32
- Support Level
- ACRS $2.01
- RMBI $14.33
- Resistance Level
- ACRS $2.16
- RMBI $14.77
- Average True Range (ATR)
- ACRS 0.10
- RMBI 0.31
- MACD
- ACRS -0.01
- RMBI -0.03
- Stochastic Oscillator
- ACRS 47.44
- RMBI 36.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.